PACTR202005622389003尚未招募3 期
Efficacy and safety of Hydroxychloroquine, Azythromycine and Zinc for the treatment of patients with SARS-Cov2 infection in Senegal: a dose ranging randomised trial. COVID-19
Faculty of Medicine University Cheikh Anta Diop of Dakar Senegal.0 个研究点目标入组 384 人开始时间: 2020年5月14日最近更新:
适应症
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 384
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19 Year(s) 至 44 Year(s)（—）
- 性别
- All
入选标准
- •(i) patients above the age of 18 with PCR confirmed covid19 infection less than 72 hours prior to randomisation,;
- •(ii) absence danger signs such as respiratory distress requiring mechanical ventilation or supplemental oxygen encephalitic disorders, renal function failure;
- •(iii) absence of known chronic illness.
排除标准
- •(i) Known allergy to any of the study medication;
- •(ii) pregnancy or breastfeeding;
- •(iii) ECG abnormality at admission;
- •(iii) Patients with ALAT/ASAT higher than 3 times the upper limit of normal on admission;
- •(iv) Patients with known chronic kidney diseases;
- •(v) Patients with known retinal diseases.
研究者
相似试验
招募中
3 期
evaluation of Safety and efficacy of anti inflammatory regimens in COVID-19COVID-19.COVID-19U07.1 COVIIRCT20200318046812N2Bagheiat-allah University of Medical Sciences906
已完成
不适用
Efficacy and safety of hydroxychloroquine for systemic/cutaneous lupus erythematosus or Sjogren's syndrome patients with annular erythema on the face and/or trunkSystemic/cutaneous lupus erythematosus Sjogren's syndromeJPRN-UMIN000004477Kanazawa University Graduate School of Medical Science10
已完成
3 期
study of hydroxychloroquine in comparison with pioglitazone in patients with type II diabetes mellitusCTRI/2009/091/001036Ipca Laboratories Limited267
已完成
4 期
to evaluate the efficacy of Hydroxychloroquine 300mg in uncontrolled T2DM who are already on two other oral anti diabetic drug.CTRI/2018/03/012842Dr Nihar Ranjan Bhattacharya30
进行中（未招募）
不适用
Efficacy of the treatment with hydroxychloroquine in non responders HIV-infected HAART-treated patients - NDHIV infection (immunological nonresponders).MedDRA version: 9.1Level: LLTClassification code 10008922EUCTR2009-012499-28-ITAZIENDA OSPEDALIERA L. SACCO (A.O. DI RILIEVO NAZIONALE)40